Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Approval in moderate-to-severe patients was based on pivotal trial results showing over…
Press Release: Sanofi and Regenerons Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine…
Description of the share buyback program approved by the Ordinary General Shareholders’ Meeting of February 12, 2026
Pursuant to Article 241-2 of the General Regulations of the French Financial…
Infineum P6188: Next Generation Additive Technology Approved Against Volkswagen’s Latest Standards
ABINGDON, England, Feb. 6, 2026 /PRNewswire/ -- Infineum, a global leader in specialty…
Press Release: Sanofi and Regenerons Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to…
Dupixent (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly…
HTX Approved for Pakistan Crypto Exchange Registration
ISLAMABAD, Pakistan, Dec. 12, 2025 /PRNewswire/ -- HTX, one of the world's…
First qualification systems for LA28 approved
10 December 2025 - The first set of qualification systems for the LA28…
LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in the United Kingdom
November 13, 2025 18:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China
September 28, 2025 19:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
